SB 1147 - Under this act, the MO HealthNet Division shall conduct an annual review of medications and forms of treatment for sickle cell disease and services for enrollees with a diagnosis of sickle cell disease, as specified in the act. The Division shall make the annual review available to the public on the Division's website and to the General Assembly. This act is substantially similar to a provision in HB 2559 (2022) and similar to a provision in the truly agreed to and finally passed CCS/HCS#2/SB 710 (2022), CCS/HCS/SS/SB 690 (2022), HCS/HB 2658 (2022), and HB 2653 (2022).
SARAH HASKINS